Genomic Health (GHDX) Oncotype DX Met Primary Endpoint in Second DCIS Treatment Study
Tweet Send to a Friend
Genomic Health (Nasdaq: GHDX) announced positive preliminary results from a second large, independent clinical validation study of Oncotype DX in ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE